Depression, PTSD and Addiction Levels Continue to Rise as Omicron Cases Increase
Data from the Mental Health Index shows that mental health in America has hit an all-time low as the COVID-19 pandemic rages on. The rates of addiction, depression and post-traumatic stress disorder are soaring, as cases of omicron increase. Currently, one in four workers in America has screened positive for PTSD. This is a 54% increase in the last three months and a 135% increase when compared to the levels recorded prior to the pandemic.
Rates of depression have also grown by 86% since fall, which is 63% higher than prepandemic levels. A significant increase in addiction in men has also been recorded, with figures showing that between September and December last year, addiction rose by 80%. Social anxiety and depression among men has also risen by 161% and 118% respectively, with data showing that general anxiety has increased by 95% in men aged between 40 and 59.
Total Brain CEO Matthew Mund stated that while seeing declines in mental health around the holidays is expected, this level was unprecedented. Mund explained that normalizing mental health discussions at the workplace and understanding the pressures and risks that exist for employees are necessary steps in addressing trauma in the workplace.
Total Brain, a mental health support and monitoring platform, compiled the Mental Health Index, which is distributed in partnership with One Mind at Work, the National Alliance of Healthcare Purchase Coalitions, the American Health Policy Institute and the HR Policy Association. CEO and president of the National Alliance Michael Thompson stated that the surge in omicron cases had affected the mental health of the workforce, noting that it was important for employers to increase their efforts to create a supportive environment as the pandemic continues.
Director of the Health Care Research and HR Policy Association Margaret Faso stated that uncertainty around federal coronavirus policies added to the stress at the workplace, noting that it was crucial that employers continue to focus on the well-being and safety of employees regardless of federal policies or mandates. Faso added that she hoped that the containment of the omicron variant would lead to a decline in the anxiety, depression and stress that workers in America experienced and improvements in the behavioral health of all Americans.
One Mind at Work executive VP Daryl Tol added that the impact of the pandemic on the mental health of the American workforce would require effort on the employers’ part as ongoing and dedicated work would be needed to implement mental health programs for employees at an effective scale.
The ever-growing scale of mental health issues has led entities such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) to devote considerable resources toward the search for a new class of treatments for these disorders in a bid to stem this tide.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Data from the Mental Health Index shows that mental health in America has hit an all-time low as the COVID-19 pandemic rages on. The rates of addiction, depression and post-traumatic stress disorder are soaring, as cases of omicron increase. Currently, one in four workers in America has screened positive for PTSD. This is a 54% increase in the last three months and a 135% increase when compared to the levels recorded prior to the pandemic.
Rates of depression have also grown by 86% since fall, which is 63% higher than prepandemic levels. A significant increase in addiction in men has also been recorded, with figures showing that between September and December last year, addiction rose by 80%. Social anxiety and depression among men has also risen by 161% and 118% respectively, with data showing that general anxiety has increased by 95% in men aged between 40 and 59.
Total Brain CEO Matthew Mund stated that while seeing declines in mental health around the holidays is expected, this level was unprecedented. Mund explained that normalizing mental health discussions at the workplace and understanding the pressures and risks that exist for employees are necessary steps in addressing trauma in the workplace.
Total Brain, a mental health support and monitoring platform, compiled the Mental Health Index, which is distributed in partnership with One Mind at Work, the National Alliance of Healthcare Purchase Coalitions, the American Health Policy Institute and the HR Policy Association. CEO and president of the National Alliance Michael Thompson stated that the surge in omicron cases had affected the mental health of the workforce, noting that it was important for employers to increase their efforts to create a supportive environment as the pandemic continues.
Director of the Health Care Research and HR Policy Association Margaret Faso stated that uncertainty around federal coronavirus policies added to the stress at the workplace, noting that it was crucial that employers continue to focus on the well-being and safety of employees regardless of federal policies or mandates. Faso added that she hoped that the containment of the omicron variant would lead to a decline in the anxiety, depression and stress that workers in America experienced and improvements in the behavioral health of all Americans.
One Mind at Work executive VP Daryl Tol added that the impact of the pandemic on the mental health of the American workforce would require effort on the employers’ part as ongoing and dedicated work would be needed to implement mental health programs for employees at an effective scale.
The ever-growing scale of mental health issues has led entities such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) to devote considerable resources toward the search for a new class of treatments for these disorders in a bid to stem this tide.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
